Trending NewsTrending NewsNASDAQ:APLS Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis $17.98 +0.17 (+0.93%) Closing price 03:48 PM EasternExtended Trading$17.93 -0.05 (-0.31%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Apellis Pharmaceuticals Stock (NASDAQ:APLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get APLS alerts:Sign Up Key Stats Today's Range$17.73▼$18.2650-Day Range$16.36▼$20.3452-Week Range$16.10▼$42.47Volume891,120 shsAverage Volume2.35 million shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice Target$39.79Consensus RatingModerate Buy Company Overview Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Read More Apellis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreAPLS MarketRank™: Apellis Pharmaceuticals scored higher than 90% of companies evaluated by MarketBeat, and ranked 298th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingApellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 11 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Apellis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.70) to ($1.06) per share.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 9.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apellis Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.39% of the float of Apellis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently increased by 0.44%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.27 Percentage of Shares Shorted21.39% of the float of Apellis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently increased by 0.44%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.53 News SentimentApellis Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Apellis Pharmaceuticals this week, compared to 9 articles on an average week.Search Interest9 people have searched for APLS on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $93,850.00 in company stock.Percentage Held by InsidersOnly 6.50% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions96.29% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apellis Pharmaceuticals' insider trading history. Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Stock News HeadlinesDavid O. Watson Sells 5,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockJune 19, 2025 | insidertrades.comApellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market MispricingJuly 2 at 11:41 PM | insidermonkey.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 3 at 2:00 AM | American Alternative (Ad)5APLS : What 13 Analyst Ratings Have To Say About Apellis PharmaceuticalsJuly 2 at 7:40 PM | benzinga.comApellis stock surges after Sobi $300 million royalty dealJuly 1 at 2:18 PM | msn.comApellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)July 1 at 9:17 AM | finance.yahoo.comApellis signs royalty purchase deal with Sobi for AspaveliJuly 1 at 9:17 AM | msn.comSobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)July 1 at 7:35 AM | prnewswire.comSee More Headlines APLS Stock Analysis - Frequently Asked Questions How have APLS shares performed this year? Apellis Pharmaceuticals' stock was trading at $31.91 on January 1st, 2025. Since then, APLS stock has decreased by 43.6% and is now trading at $17.9850. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.38. The firm's quarterly revenue was down 3.2% compared to the same quarter last year. Read the conference call transcript. Does Apellis Pharmaceuticals have any subsidiaries? Apellis Pharmaceuticals subsidiaries include Potentia Pharmaceuticals, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., and more. When did Apellis Pharmaceuticals IPO? Apellis Pharmaceuticals (APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apellis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2025Today7/03/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLS CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees770Year Founded2009Price Target and Rating Average Stock Price Target$39.79 High Stock Price Target$83.00 Low Stock Price Target$18.00 Potential Upside/Downside+121.2%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$197.88 million Net Margins-28.83% Pretax Margin-28.66% Return on Equity-99.19% Return on Assets-25.35% Debt Debt-to-Equity Ratio2.76 Current Ratio4.08 Quick Ratio3.62 Sales & Book Value Annual Sales$781.37 million Price / Sales2.89 Cash FlowN/A Price / Cash FlowN/A Book Value$1.84 per share Price / Book9.77Miscellaneous Outstanding Shares125,680,000Free Float117,513,000Market Cap$2.26 billion OptionableOptionable Beta0.67 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:APLS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
